Anti-HIV Agents
Research News and Information

Saturday, November 21, 2009

A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function.

15 Nov 2009 The innate antiviral factor APOBEC3G (A3G) possesses RNA binding activity and deaminates HIV-1 DNA. High-molecular mass forms of A3G can be isolated from a variety of cell types but exhibit limited deaminase activity relative to low-molecular mass ... Read more...

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.

30 Oct 2009 BACKGROUND: Achieving virologic suppression is a clear therapeutic goal for patients receiving combination antiretroviral therapy (cART). However, the effects of immunologic responses, whether measured as CD4 count changes from baseline or CD4 ... Read more...

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

30 Oct 2009 BACKGROUND: Boosted darunavir (DRV/r) plus etravirine (ETR), in DUET trials, and raltegravir, in BENCHMRK trials, showed high rates of virologic response in patients with multidrug-resistant HIV-1 infection, particularly when associated with two ... Read more...

Latest indexed articles for 'Anti-HIV Agents'

These are the very latest articles for this heading:

• Nanotechnology for antiretroviral drug delivery. 29 Nov 2009
• A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function. 15 Nov 2009
• Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. 30 Oct 2009
• Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. 30 Oct 2009
• Gender differences in discontinuation of antiretroviral treatment regimens. 30 Oct 2009
• Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. 30 Oct 2009
• Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. 30 Oct 2009
• Molecular characterization of a full-length genome of a HIV-2 isolate from India. 30 Oct 2009
• Prevention of breast milk transmission of HIV: the time is now. 30 Oct 2009
• Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. 30 Oct 2009
• Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. 30 Oct 2009
• Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. 30 Oct 2009
• Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. 30 Oct 2009
• Increased peripheral proinflammatory cytokines in HIV-1-infected patients with prolonged viral suppression suffering from high psychological stress. 30 Oct 2009
• Universal access not a dream. 30 Oct 2009
• HIV drug patents in the spotlight. 30 Oct 2009
• The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly. 30 Oct 2009
• Mobilising the community in the fight against HIV/AIDS. 29 Oct 2009
• Clinical practice. Postexposure prophylaxis for HIV infection. 27 Oct 2009
• Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis. 14 Oct 2009

See a longer list of these articles.

Technical information about 'Anti-HIV Agents'

Definition: Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

Registry Number: 0

Descriptor UI: D019380

Alternative terms: Anti-HIV Agents; Agents, Anti-HIV; Anti HIV Agents; Anti-HIV Drugs; Anti HIV Drugs; Drugs, Anti-HIV; AIDS Drugs; Drugs, AIDS; Anti-AIDS Agents; Agents, Anti-AIDS; Anti AIDS Agents; Anti-AIDS Drugs; Anti AIDS Drugs; Drugs, Anti-AIDS;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.122.388.077.088;

History Note: 97

Technical Notes: consider also AIDS /drug ther; may be used for articles on simian acquired immunodefic syndrome & simian immunodefic virus